Business Context and Reporting Period
Company: Biomerica, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: May 31, 2009
Business Overview: Biomerica develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care settings (physicians' offices and over-the-counter). Products include tests for chronic diseases, hormones, and antibodies. Manufacturing is split between Newport Beach, California, and Mexicali, Mexico.
Key Financial Metrics
| Metric | Fiscal 2009 | Fiscal 2008 |
|---|---|---|
| Net Sales | $4,934,771 | $4,926,505 |
| Cost of Sales | 60.0% of Sales | 56.7% of Sales |
| Research & Development | $278,308 | $259,085 |
| Interest Expense | $27,521 | $49,542 |
| Cash and Equivalents | $1,595,823 | $2,022,380 |
| Working Capital | $3,831,112 | $3,428,936 |
| Backlog | $97,000 | $346,000 |
Debt and Liquidity: As of May 31, 2009, the company held a $400,000 line of credit with Union Bank of California (unused) and an equipment loan balance of $122,781. The company repaid shareholder debt of $95,936 during the fiscal year.
Material Changes vs. Prior Period
- Revenue: Net sales remained flat, increasing only $8,266 (0%) from the prior year.
- Profitability Pressure: Cost of sales increased by 6.2% ($174,025), raising the cost-to-sales ratio from 56.7% to 60.0%. This was driven by write-offs of new product scrap, obsolete inventory, and increased reserves for slow-moving inventory.
- Operating Expenses: Selling, general, and administrative (SG&A) costs rose 5.6% ($76,848) due to increased bad debt reserves, Sarbanes-Oxley consulting, and startup costs for a new European subsidiary.
- One-Time Income: Other income decreased by $1,132,370 compared to 2008, primarily due to the absence of one-time gains from the sale of Lancer Orthodontics and a warrant sale in the prior year.
- Cash Flow: Cash used in operations decreased to $101,999 in 2009 from $194,595 in 2008. However, cash used in investing activities was $215,890 in 2009, compared to cash provided by investing activities of $1,515,695 in 2008 (which included proceeds from asset sales).
Outlook, Risks, and Management Commentary
Management Commentary: Management anticipates increasing R&D efforts for new product development and approvals in the upcoming fiscal year. The company is relocating operations to a new facility in Irvine, California, with a lease commencing September 1, 2009.
Risks and Contingencies:
- Customer Concentration: Two customers accounted for 26% of consolidated sales in 2009 (down from 29% in 2008).
- Regulatory Compliance: Products are subject to FDA and international regulations. Failure to maintain compliance could result in fines, recalls, or suspension of production.
- Product Liability: Manufacturing and marketing entail product liability risks; insurance coverage may not be sufficient.
- Foreign Operations: Significant revenue (53.3%) comes from Europe. Risks include economic factors, government regulations, and import restrictions in foreign markets.
- Intellectual Property: The company relies on patents and trademarks but faces competition from larger entities with greater resources.
Investor Verification Checklist
- Inventory Valuation: Verify the adequacy of reserves for obsolete and slow-moving inventory, which significantly impacted margins in 2009.
- Customer Concentration: Assess the stability of the two largest customers representing over a quarter of total revenue.
- Regulatory Status: Confirm the FDA clearance status of key products, noting that several are currently sold internationally or "For Research Only" in the U.S.
- Cash Burn vs. Liquidity: Monitor the trend of cash used in operations against the $1.6 million cash balance to ensure sufficient runway for the planned facility relocation and R&D expansion.
- Debt Covenants: Review the terms of the $400,000 line of credit and the $122,781 equipment loan to ensure compliance with covenants, particularly the requirement to maintain a zero balance on the line of credit for 30 consecutive days annually.